Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.910
-0.010 (-0.34%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
6.44M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| FibroBiologics | 15 |
| BioRestorative Therapies | 14 |
| Purple Biotech | 10 |
| Immuron | 7 |
| Akari Therapeutics, | 6 |
| Silo Pharma | 3 |
| Xenetic Biosciences | 2 |
CANF News
- 4 weeks ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 4 weeks ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 4 weeks ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus
- 6 weeks ago - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - GlobeNewsWire
- 7 weeks ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 7 weeks ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 7 weeks ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus